Clinical Trial

TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment

Staff February 22, 2023

BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively...

HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)

Staff February 22, 2023

In vitro and in vivo results demonstrated HC-7366 is a potent GCN2 activator with strong antitumor activity in AML as...

Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

Staff February 22, 2023

NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has cleared the U.S....

Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug

Staff February 22, 2023

BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing...

SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds

Staff February 22, 2023

Clearmind Medicine submitted patent applications to protect the novel compoundsTel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....

INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2

Staff February 21, 2023

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Feb. 21, 2023...

Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder

Staff February 21, 2023

Type C meeting with FDA set for Second Quarter Plans in Place to Meet with Multiple Regulatory Agencies Throughout Europe...

Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives

Staff February 21, 2023

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from...

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

Staff February 21, 2023

-- Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial Topline Safety, Tolerability and Immunogenicity...

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

Staff February 21, 2023

FREMONT, CA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...

eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

Staff February 21, 2023

Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 21, 2023...

Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Staff February 21, 2023

WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023

Staff February 21, 2023

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...

Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023

Staff February 21, 2023

CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...

Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarité FTQ

Staff February 21, 2023

MONTRÉAL, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Esperas Pharma, Inc. (“Esperas”), a company based in Montréal, Québec, today announced a...

Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents

Staff February 21, 2023

Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United StatesIf approved, roflumilast foam...

Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

Staff February 21, 2023

NEW YORK and LONDON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...

Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors

Staff February 20, 2023

Gilbert Ghostine, CEO of the Swiss multi-national fragrances business Firmenich appointed Chairman-Designate of the future Sandoz BoardMr Ghostine to begin...

FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review

Staff February 20, 2023

Saint-Herblain (France), February 20, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that...

Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

Staff February 19, 2023

SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an IRS Form 8937...

Clinical Trial

TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment

HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)

Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug

SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds

INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2

Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder

Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023

Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023

Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarité FTQ

Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents

Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors

FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review

Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

2026 Payer IT Outsourcing Outlook: Outcome-Based Managed Services, Production-Grade GenAI Governance, and Vendor-Risk Enforcement

Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody’s Ratings Agency Revises Outlook to Positive

PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements

You may have missed